Artificial Retina Market Size, Share & Industry Analysis, By Product Type (Epiretinal Prostheses, Subretinal Prostheses, Suprachoroidal Prostheses, and Others), By Application (Retinitis Pigmentosa, Geographic Atrophy, Stargardt Disease & Macular Dystrophies, and Others), By End User (Specialty Ophthalmology Centers, Hospitals & Academic Medical Centers, Research Institutes, and Others), and Regional Forecast, 2026–2034

The global artificial retina market size was valued at USD 6.2 million in 2025. The market is projected to grow from USD 16.3 million in 2026 to USD 605.3 million by 2034, exhibiting a CAGR of 57.1% during the forecast period.

Artificial retina systems, also known as retinal prostheses or retinal implants, are implantable medical technologies designed to provide visual perception or restore a degree of functional vision in individuals affected by severe retinal degeneration. These systems generally bypass damaged photoreceptor cells and stimulate surviving retinal neurons through electrical, photovoltaic, or related neurostimulation approaches. The market is primarily driven by technological advancements in retinal neurostimulation, growing clinical research into vision restoration, increasing development of photovoltaic and wireless implants, expansion of clinical trials for advanced retinal degenerative diseases, and the substantial unmet need among patients with irreversible vision loss. In addition, increasing research targeting geographic atrophy, retinitis pigmentosa, Stargardt disease, and other inherited or degenerative retinal conditions is expanding the potential addressable population.

• For instance, in October 2025, results from the PRIMAvera clinical study of Science Corporation's PRIMA photovoltaic subretinal implant were published in the New England Journal of Medicine. The study evaluated 38 patients with geographic atrophy due to age-related macular degeneration and reported clinically meaningful visual-acuity improvement in 26 of the 32 participants assessed at 12 months.

Furthermore, Science Corporation, Nano-Retina Ltd., NIDEK CO., LTD., BIONIC VISION TECHNOLOGIES PTY LTD, and IntelliMicro Medical Co., Ltd. are among the prominent companies operating in the global market.

ARTIFICIAL RETINA MARKET TRENDS

Increasing Development of High-Resolution Photovoltaic Retinal Prostheses to Transform Vision Restoration

Increasing development of wireless and photovoltaic retinal implants represents a major trend in the market. Earlier retinal prostheses primarily relied on relatively low-resolution electrode arrays connected to external image-processing systems, whereas newer technologies are being designed to improve spatial resolution, simplify power delivery, reduce implanted hardware requirements, and provide more useful visual perception. In addition, photovoltaic subretinal implants can convert projected near-infrared light into electrical stimulation within the retina, while advanced image-processing glasses and external processors can modify visual information before it reaches the implant.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Increasing Clinical Development of Retinal Prostheses for Irreversible Vision Loss to Drive Market Growth

Growing clinical development of retinal prostheses for patients with advanced and currently irreversible retinal degeneration is a major factor driving the global artificial retina market growth. Diseases such as retinitis pigmentosa, geographic atrophy associated with age-related macular degeneration, Stargardt disease, and other inherited retinal dystrophies can lead to progressive destruction of photoreceptors while portions of the inner retinal neural network remain capable of stimulation. In addition, artificial retina technologies aim to utilize these remaining neural pathways to generate visual perception when conventional optical correction or pharmacological treatment cannot restore lost vision. Moreover, increasing numbers of feasibility studies, long-term follow-up programs, multicenter clinical investigations, and translational research projects are helping developers establish safety, surgical feasibility, functional outcomes, and suitable patient-selection criteria.

MARKET RESTRAINTS

High Development Costs and Limited Commercial Availability to Restrict Market Penetration

High research and development expenses, complex regulatory pathways, specialized surgical requirements, and limited current commercialization represent major restraints to the market. Moreover, retinal prosthesis development requires integration of implantable electronics, biocompatible materials, neurostimulation components, image-processing software, external hardware, specialized surgical procedures, and long-term rehabilitation. Developers must demonstrate not only device safety and durability but also meaningful improvements in visual function and quality of life among relatively small and highly selected patient populations. These factors can delay market entry and limit near-term availability outside major academic ophthalmology centers and clinical research programs.

MARKET OPPORTUNITIES

Expansion into Geographic Atrophy and Broader Retinal Degenerative Indications to Create Significant Opportunities

Expansion of artificial retina technologies beyond end-stage retinitis pigmentosa into geographic atrophy and other forms of retinal degeneration represents a significant growth opportunity. Earlier retinal prostheses primarily targeted individuals with profound blindness resulting from inherited retinal disease, limiting the addressable population. Newer subretinal photovoltaic systems are being evaluated in patients with geographic atrophy associated with advanced dry age-related macular degeneration, where central photoreceptors are lost but peripheral natural vision may remain. Successful restoration of central visual function while preserving peripheral vision could substantially broaden the clinical relevance of retinal prostheses.

MARKET CHALLENGES

Achieving Clinically Meaningful Visual Resolution and Long-Term Implant Performance to Challenge Developers

Achieving sufficient visual resolution, long-term implant stability, patient usability, and durable clinical benefit remains one of the most significant challenges in artificial retina development. Retinal neural stimulation does not reproduce natural vision directly, and patients generally require substantial rehabilitation to interpret artificial visual information. Clinical outcomes can vary depending on disease severity, surviving retinal architecture, implant placement, electrode or pixel density, neural interface quality, image-processing algorithms, and patient adaptation. Long-term implants must also remain mechanically stable and biocompatible while operating reliably within the ocular environment.

Segmentation Analysis

By Product Type

Development For Geographic Atrophy Supported Subretinal Prostheses Segment Dominance

Based on product type, the market is segmented into epiretinal prostheses, subretinal prostheses, suprachoroidal prostheses, and others.

The subretinal prostheses segment accounted for the highest artificial retina market share in 2025. Subretinal implants are positioned beneath the retina and are designed to stimulate surviving retinal neurons at a location corresponding closely with the natural photoreceptor layer. Moreover, growing clinical interest in photovoltaic subretinal implants, potential advantages related to retinotopic stimulation, and development for geographic atrophy are strengthening this segment.     

The suprachoroidal prostheses segment is expected to register highest CAGR of 62.7% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Application

Established Retinal Prosthesis Research Supported Retinitis Pigmentosa Segment Dominance

Based on application, the market is segmented into retinitis pigmentosa, geographic atrophy, stargardt disease & macular dystrophies, and others.

The retinitis pigmentosa segment accounted for the highest market share in 2025. The segment growth is attributed to the historical focus of retinal prosthesis development on patients with severe inherited photoreceptor degeneration. Several pioneering retinal implants were initially developed for individuals with advanced retinitis pigmentosa because inner retinal neurons may remain sufficiently intact even after extensive photoreceptor loss.

The stargardt disease & macular dystrophies segment is anticipated to register a considerable CAGR of 69.6% during the forecast period.

By End User

Established Research Infrastructure Supported Research Institutes Segment in Early Market Stage

Based on end user, the market is segmented into specialty ophthalmology centers, hospitals & academic medical centers, research institutes, and others.

Research institutes segment accounted for the highest market share in 2025. Retinal prosthesis programs currently depend heavily on multidisciplinary research involving ophthalmologists, retinal surgeons, neuroscientists, biomedical engineers, microelectronics researchers, image-processing specialists, rehabilitation experts, and medical-device developers. In addition, universities and research institutes therefore play a major role in prototype development, preclinical testing, feasibility studies, and technology transfer.

The specialty ophthalmology centers segment is projected to register the highest CAGR of 64.8% during the forecast period.

Artificial Retina Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held a considerable share in 2024, valuing at USD 1.3 million, and generated revenue of USD 1.7 million in 2025. The growth of the North American market is supported by substantial investment in neurotechnology, retinal disease research, biomedical engineering, advanced ophthalmology, and implantable medical devices.

U.S. Artificial Retina Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 2.1 million in 2026, accounting for roughly 12.7% of global artificial retina sales.

Europe

Europe is projected to record a considerable growth rate of 47.3% in the coming years, and reach a dominant valuation of USD 10.2 million by 2026. Europe's market leadership is supported by its long-standing role in retinal prosthesis research, clinical evaluation, ophthalmic surgery, and early regulatory approvals.

U.K. Artificial Retina Market

The U.K. market is estimated at around USD 0.9 million in 2026, representing roughly 5.3% of global revenues.

Germany Artificial Retina Market

Germany’s market is projected to reach approximately USD 3.8 million in 2026, equivalent to around 23.2% of global sales.

Asia Pacific

Asia Pacific is estimated to hold considerable share in the global market and is estimated to reach USD 3.3 million in 2026. Growth is supported by increasing investment in ophthalmic research, expansion of advanced retinal surgery centers, development of neuroengineering capabilities, and growing research into retinal prostheses across Japan, Australia, China, and other regional markets.

Japan Artificial Retina Market

The Japanese market is estimated at around USD 0.8 million in 2026, accounting for roughly 5.1% of global revenues.

China Artificial Retina Market

China’s market is projected to be one of the largest globally, with 2026 revenues estimated at around USD 0.9 million, representing roughly 5.7% of global sales.

India Artificial Retina Market

The Indian market is estimated at around USD 0.3 million in 2026, accounting for roughly 1.6% of global revenues.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa regions are expected to witness moderate growth in this market during the forecast period. The Latin America market is set to reach a valuation of USD 0.3 million in 2026. The market in Latin America and the Middle East & Africa is expected to grow due to improving access to specialized ophthalmic care and increasing investments in advanced eye care infrastructure. Countries such as Brazil, Mexico, Saudi Arabia, and the UAE are strengthening retinal disease management services, while expanding clinical research collaborations and technological advancements are creating opportunities for the future adoption of retinal prosthetic devices.

GCC Artificial Retina Market

The GCC market is set to reach a value of USD 0.1 million in 2026.

South Africa Artificial Retina Market

The South African market is projected to reach around USD 0.1 million in 2026, representing roughly 0.3% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Focus on Clinical Innovation and Next-Generation Retinal Prosthesis Development by Key Players to Expand Market Share

The global artificial retina market has a semi-consolidated competitive structure, comprising prominent players such as Science Corporation, Nano-Retina Ltd., NIDEK CO., LTD., BIONIC VISION TECHNOLOGIES PTY LTD, and IntelliMicro Medical Co., Ltd. These market participants are focusing on higher-resolution stimulation, wireless power delivery, improved implant biocompatibility, simplified surgical implantation, image-processing technologies, clinical-trial expansion, and broader retinal disease indications.

• For instance, in April 2024, Science Corporation acquired the intellectual property and other assets associated with Pixium Vision's PRIMA retinal prosthesis and announced plans to continue and expand development of the subretinal technology.

Other notable players in the global market Zhejiang Nurotron Biotechnology Co., Ltd., SHENZHEN SIBIONICS CO., LTD., Hangzhou Nanochap Electronics Co., Ltd., iBIONICS Inc., and LambdaVision, Inc. These companies are expected to prioritize collaborations to increase their global market share during the forecast period.

LIST OF KEY ARTIFICIAL RETINA COMPANIES PROFILED IN REPORT

• Science Corporation (U.S.)
• Nano-Retina Ltd. (Israel)
• NIDEK CO., LTD. (Japan)
• BIONIC VISION TECHNOLOGIES PTY LTD (Australia)
• IntelliMicro Medical Co., Ltd. (China)
• Zhejiang Nurotron Biotechnology Co., Ltd. (China)
• SHENZHEN SIBIONICS CO., LTD. (China)
• Hangzhou Nanochap Electronics Co., Ltd. (China)
• iBIONICS Inc. (Canada)
• LambdaVision, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS

• March 2026: Science Corporation raised USD 230 million in Series C financing to support the commercialization of its PRIMA retinal implant and expand clinical trials into additional retinal diseases, including retinitis pigmentosa and Stargardt disease.
• January 2026: NIDEK CO., LTD. registered a clinical trial in Japan for its retinal prosthesis system based on suprachoroidal-transretinal stimulation (STS) for patients with advanced outer retinal degeneration. The study represents continued clinical development of an alternative retinal stimulation approach for vision restoration.
• January 2025: Bionic Vision Technologies published long-term clinical findings for a second-generation 44-channel suprachoroidal retinal prosthesis, demonstrating implant stability and a favorable safety profile over approximately two years in patients with advanced retinitis pigmentosa.
• September 2022: Nano Retina presented interim clinical outcomes for its NR600 retinal prosthesis at EURETINA 2022.
• January 2022: Moorfields Eye Hospital implanted the PRIMA System in the first U.K. patient participating in a Europe-wide clinical study of the retinal prosthesis for geographic atrophy associated with dry age-related macular degeneration.

REPORT COVERAGE

The global artificial retina market analysis includes a comprehensive study of the market size & forecast by all the market segments included in the report. It includes details on the market dynamics and market trends expected to drive the market over the forecast period. It provides information on key aspects, including an overview of technological advancements, the regulatory environment, and product launches. Additionally, it details partnerships, mergers & acquisitions, as well as key industry developments and investments by key regions. The global market research report also provides a depth competitive landscape with information on the market share and profiles of key operating players.

Request for Customization   to gain extensive market insights.

 Report Scope & Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1: Country-Level Eligible Patient & Retinal Prosthesis Adoption Analysis

• Estimate country-level patient populations affected by retinitis pigmentosa, geographic atrophy, Stargardt disease & macular dystrophies, and other retinal degenerative conditions potentially addressable by artificial retina technologies.
• Assess disease prevalence, severity of photoreceptor degeneration, remaining retinal function, diagnosis rates, and clinical eligibility for retinal prosthesis implantation.
• Estimate the proportion of eligible patients with access to specialty ophthalmology centers, retinal surgeons, and advanced vision-restoration programs.
• Assess potential adoption based on clinical evidence, regulatory approval, reimbursement, patient willingness, and availability of artificial retina systems.
• Calculate market value using:
• Eligible Patient Population × Clinical Eligibility Rate × Artificial Retina Penetration × Implantation Rate × Average Selling Price.
• Aggregate individual country estimates into regional and global market totals.

Approach 2: Implant Volume, Product Type & ASP Analysis

• Estimate annual artificial retina implantation volumes by epiretinal prostheses, subretinal prostheses, suprachoroidal prostheses, and other emerging retinal prosthesis technologies.
• Assess implantation volumes across retinitis pigmentosa, geographic atrophy, Stargardt disease & macular dystrophies, and other retinal degenerative conditions.
• Estimate utilization across specialty ophthalmology centers, hospitals & academic medical centers, research institutes, and other end users.
• Determine average selling prices based on implant technology, device configuration, external processing components, geographic market, clinical setting, and commercialization stage.
• Account separately for clinical-trial implants, early-access procedures, and commercially implanted systems where applicable.
• Cross-check estimates using clinical-trial enrollment, reported implantation volumes, developer disclosures, regulatory information, hospital data, and published clinical studies.

Approach 3: Clinical Pipeline, Regulatory & Institutional Data Cross-Check

• Validate market assumptions using clinical trial registries, regulatory agencies, ophthalmology associations, academic medical centers, retinal research institutes, scientific literature, and company disclosures.
• Track clinical development programs for epiretinal, subretinal, suprachoroidal, photovoltaic, and other retinal prosthesis technologies.
• Assess regulatory status, clinical-trial phases, patient enrollment, implantation numbers, safety outcomes, and visual-function outcomes.
• Review technological advances in retinal neurostimulation, photovoltaic implants, electrode arrays, wireless power delivery, implant miniaturization, image processing, and implant biocompatibility.
• Assess expected commercialization timelines and potential expansion from research settings into specialized clinical practice.
• Exclude ocular/artificial eye prostheses, artificial iris implants, intraocular lenses, cortical visual prostheses, and unrelated ophthalmic implants from the artificial retina market.

2. Top Down Approaches

Approach 1: Developer Revenue, Funding & Commercialization Analysis

• Estimate artificial-retina-related revenues and potential revenues generated by retinal prosthesis developers, neurotechnology companies, ophthalmic implant companies, and relevant technology developers.
• Isolate revenues attributable to retinal prosthesis systems, implant components, external processors, implantation-related device sales, and directly associated artificial retina technologies.
• For pre-commercial companies, assess clinical development expenditure, funding, acquisitions, strategic investments, regulatory milestones, and announced commercialization plans.
• Estimate potential revenues for emerging developers using projected implant volumes, average system pricing, addressable patient populations, geographic rollout, and expected regulatory approvals.
• Exclude revenue generated from unrelated neural implants, cortical brain-computer interfaces, conventional ophthalmic implants, pharmaceuticals, and other medical-device businesses.
• Compare aggregated developer-derived estimates with bottom-up patient eligibility and implantation-volume calculations.

Approach 2: Clinical Pipeline, Commercialization & Market Opportunity Analysis

• Compare developer- and pipeline-derived market estimates with:
• Retinitis pigmentosa patient population
• Geographic atrophy patient population
• Stargardt disease & macular dystrophy populations
• Clinically eligible patient population
• Clinical-trial enrollment
• Artificial retina implantation volumes
• Regulatory approvals
• Retinal surgeon availability
• Specialty ophthalmology center availability
• Artificial retina system ASPs
• Reimbursement availability
• Clinical outcomes
• Commercialization timelines
• Adjust for differences between research-stage implants, clinical-trial devices, early-access systems, and commercially available artificial retina technologies to avoid double counting.
• Forecast individual country markets before regional and global aggregation.
• Develop forecasts using:
• Clinical-trial success
• Regulatory approvals
• Commercialization of next-generation retinal prostheses
• Expansion into geographic atrophy
• Development for inherited retinal diseases
• Advances in photovoltaic retinal implants
• Improvements in visual resolution
• Expansion of specialty ophthalmology centers
• Increasing neurotechnology investment
• Reimbursement development
• Manufacturing scale-up
• Geographic market expansion

3. List of Key Sources

• ClinicalTrials.gov
• U.S. Food and Drug Administration (FDA)
• European regulatory authorities and databases
• National regulatory agencies
• Ophthalmology associations
• Retina specialist organizations
• Academic medical centers
• Specialty ophthalmology centers
• Retinal research institutes
• Artificial retina and neurotechnology developers
• Company annual reports and investor presentations
• Company press releases
• Clinical trial publications
• Peer-reviewed ophthalmology journals
• Retinal disease foundations and patient organizations
• Government health databases
• Disease prevalence and epidemiology databases
• Patent databases
• Scientific conference proceedings
• Regulatory submissions and approval databases
• Published retinal prosthesis implantation studies

4. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents:
  • Artificial retina developers, retinal prosthesis manufacturers, neurotechnology companies, biomedical engineers, implant designers, microelectronics specialists, retinal neurostimulation researchers, clinical-development executives, regulatory professionals, product developers, and business-development executives.
  • Validate implant volumes, ASPs, product pipeline, technology type, clinical development status, regulatory timelines, commercialization plans, manufacturing capacity, clinical-trial activity, geographic expansion, and future indications.

Demand Side Interviews: 40%

• Key Respondents:  
  • Retina specialists, vitreoretinal surgeons, ophthalmologists, specialty ophthalmology centers, hospitals & academic medical centers, clinical investigators, low-vision rehabilitation specialists, hospital procurement professionals, and retinal disease patient organizations.
  • Validate patient eligibility, clinical demand, implantation criteria, referral patterns, physician willingness, visual-function expectations, rehabilitation requirements, access barriers, reimbursement, adoption potential, and future utilization of artificial retina systems.